Company intelligence / Profile preview

VR1

New York City, New York, United States

Ownership: Private
Employees: ~5
Development stage: Other

Overview

Ausanil, the lead product from VR1 Inc., provides rapid pain relief for headaches and migraines—reportedly within three minutes. It is over-the-counter, affordable compared to competitors like Excedrin, non-habit forming, has no known drug interactions or systemic side effects, and has been recommended by hundreds of physicians. As of May 2015 it had $200K cumulative revenue with strong growth projections

Therapeutic areas: Neurology
Modalities: Small moleculeNon-pharmacological therapy
Industry: Biotech

Drug pipeline

1 asset

ausanil

Discontinued

Partnerships

Distribution agreements with US pharmacy chains/distributors are mentioned but not named specifically.

Beyond the preview

Go deeper on VR1.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VR1.

Explore the full profile